A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with postmenopausal osteoporosis on bone microarchitecture measured by high resolution peripheral-Quantitative Computed Tomography (p-QCT) Assess the effects of strontium ranelate in comparison with alendronate on the bone microarchitecture in patients with postmenopausal osteoporosis

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Follow-up trial with no study drug prescription in diabetic patients previously included in the REGULATE trial To document the clinical condition of patients who were included in the REGULATE trial and exposed to the investigational drugs (benfluorex or pioglitazone).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years To determine the optimal dose of ivabradine to reach the target heart rate reduction (HRR) of 20% without inducing a bradycardia (i.e. HR should be greater than a predefined HR threshold by age subset...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris. A 6-week randomised double-blind parallel-group international multicentre study - To demonstrate that over a 6-week treatment period ivabradine is more efficacious than placebo when given in combination with calcium antagonists (amlodipine or nifedipine) in patients with stable c...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A 9 week pilot, open labelled, international multicenter study The primary objective is to evaluate the effects of 3 oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine on heart rate, systolic and diastolic blood pressure, left ventricular volumes and function in ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase I dose-escalation study of S 78454 in patients with solid tumour Not provided at time of registration and not expected to be available in the future

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function ­To demonstrate the beneficial effect of ivabradine compared with placebo on endothelial function as measured by flow mediated dilation (FMD) of the brachial artery at 12 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release gliclazide-based regimen for the prevention of vascular disease among high risk individuals with type 2 diabetes To determine the effects of a fixed low-dose perindopril-indapamide combination (2mg/0.625mg) vs placebo and a modified-release gliclazide (30-120mg)-based intensive glucose lowering regimen vs standa...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day oral 8 mg perindopril morning administration versus evening administration in hypertensive patients. An 8-week, 2-arm, randomised, double-blind study To assess a 38h-ABPM the blood pressure decrease (DBP during daytime) from baseline to study end with a validated ABPM device, after an 8-week treatment period with perindopril, administered either at...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex versus an oral anti-diabetic in combination with sulfonylurea administered orally for the treatment of type two diabetes Not provided at time of registration and not expected to be available in the future

• Pays France
• Organes Aucun
• Spécialités Aucune